Zobrazeno 1 - 10
of 80
pro vyhledávání: '"O. VERIER-MINE"'
Autor:
Bruno Guerci, Agnès Smagala, Laurent Meyer, Sophie Borot, F. Dorey, Patrice Winiszewski, Nicolas Meyer, Thierry Hannedouche, Laurence Kessler, Dominique Fleury, O. Verier-Mine, Farideh Alenabi, Didier Ducloux, François Chantrel, Kristian Kunz, Philippe Baltzinger, Joëlle Cridlig, Marion Munch, Alexandre Klein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a717138b6edd67bde1d4674c5bbb0b6e
https://doi.org/10.1111/dom.13988/v2/response1
https://doi.org/10.1111/dom.13988/v2/response1
Autor:
P.Y. Benhamou, G. Charpentier, Sylvia Franc, Bruno Guerci, Pauline Schaepelynck, B. Catargi, A. Penfornis, E. Bonnemaison, N. Tubiana, Nathalie Jeandidier, Isabelle Guilhem, Didier Gouet, N Filhol, Eric Renard, C. Guillot, Yves Reznik, C. Atlan, E. Bismuth, V. Melki, Sabine Rudoni, E. Merlen, Michael Joubert, A. Sola-Gazagnes, Anne Farret, Sophie Borot, S Picard, J.P. Riveline, Hélène Hanaire, O. Verier-Mine
Publikováno v:
Médecine des Maladies Métaboliques. 11:S1-S37
Autor:
O. Verier-Mine, Thierry Hannedouche, Bruno Guerci, Patrice Winiszewski, Kristian Kunz, Farideh Alenabi, Alexandre Klein, Nicolas Meyer, Philippe Baltzinger, François Chantrel, Samy Hadjadj, Didier Ducloux, Laurent Meyer, Joëlle Cridlig, Marion Munch, F. Dorey, Laurence Kessler, Dominique Fleury, Sophie Borot, Agnès Smagala
Publikováno v:
Diabetes, obesitymetabolismREFERENCES. 22(6)
AIM To evaluate the effect of adding the dipeptidyl-peptidase-4 inhibitor vildagliptin to insulin on the glycaemic control of patients with type 2 diabetes undergoing haemodialysis. METHODS Overall, 65 insulin-treated patients with type 2 diabetes un
Autor:
Sylvie Dejager, J.F. Gautier, P. Monguillon, Bernard Charbonnel, B. Fiquet, Paul Valensi, O. Verier-mine
Publikováno v:
Diabetes Research and Clinical Practice. 116:26-28
We conducted a pilot study to evaluate two therapeutic strategies at the time of insulin initiation in type 2 diabetic patients insufficiently controlled with metformin+insulin-secretagogues (IS, sulfonylureas or glinides). Patients were randomized t
Autor:
M.-C. Vantyghem, F. Defrance, D. Quintin, C. Leroy, V. Raverdi, G. Prévost, R. Caiazzo, J. Kerr-Conte, F. Glowacki, M. Hazzan, C. Noel, F. Pattou, A.S. Balavoine, R. Bresson, M.F. Bourdelle-Hego, M. Cazaubiel, M. Cordonnier, D. Delefosse, F. Dorey, A. Fayard, C. Fermon, P. Fontaine, C. Gillot, S. Haye, A.C. Le Guillou, W. Karrouz, C. Lemaire, M. Lepeut, R. Leroy, B. Mycinski, E. Parent, C. Siame, A. Sterkers, F. Torres, O. Verier-Mine, E. Verlet, R. Desailloud, A. Dürrbach, M. Godin, J.D. Lalau, C. Lukas-Croisier, E. Thervet, O. Toupance, Y. Reznik, P.F. Westeel
Publikováno v:
Diabetes & Metabolism. 40:108-119
Type 1 diabetes (T1D) is due to the loss of both beta-cell insulin secretion and glucose sensing, leading to glucose variability and a lack of predictability, a daily issue for patients. Guidelines for the treatment of T1D have become stricter as res
Autor:
L. Bordier, M. Buysschaert, B. Bauduceau, J. Doucet, C. Verny, V. Lassmann Vague, J.P. Le Floch, B Bauduceau, J-F Blicklé, I Bourdel-Marchasson, T Constans, J Doucet, A Fagot-Campagna, E Kaloustian, V Lassmann-Vague, P Lecomte, D Tessier, C Verny, U Vischer, H Affres, M Alix, F Archambeaud, Z Barrou, P Beau, S Beltran, C Benoit, J-P Beressi, F Bernachon, C Berne, G Berrut, A Blaimont, J-F Blickle, M Boda-Buccino, J Bohatier, P Böhme, L Bordier, K Bouchou, B Bouillet, F Bouilloud, R Bouix, E Boulanger, C Bourgon, E Bourrinet, P Brocker, I Bruckert, C Capet, C Carette, B Cariou, A Carreau, C Chaillou Vaurie, S Chamouni, C Ciangura, C Collet-Gaudillat, M-E Combes-Moukhovsky, M Cordonnier, A Cuperlier, D Dambre, J D'Avigneau, P De Botton, V Degros, F Delamarre-Damier, S Denat, F Desbiez, B Deumier, F Dorey, E Dresco, A Drutel, E Du Rosel De Saint Germain, D Dubois-Laforgue, B Duly-Bouhanick, O Dupuy, L Dusselier, S Faucher-Kareche, S Fendri, P Fontaine, S Galinat, A Gentric, H Gin, F Glaise, T Godeau, B Gonzales, I Got, B Guerci, P-J Guillausseau, S Hadjadj, Y Hadjali, M Halbron, S Halimi, C Halter, H Hanaire, V Hardy, A Hartemann-Heurtier, J-P Haulot, F Hequet, M Issa-Sayegh, P Jan, N Jeandidier, H Joseph-Henri, I Julier, V Kerlan, T Kharitonnoff, M Ladsous, L Lahaxe, M-P Lamaraud, E Lassenne, J-M Lecerf, I Leroux, S Lesven, M Levy, S Lopez, F Makiza, P Manckoundia, C Marquis Pomeau, H Mayaudon, S Micheli, R Mira, F Monnier, H Mosnier-Pudar, N Neri, I Normand, M Paccalin, C Pagu, D Paris, A Penfornis, J-L Perie, J-M Petit, G Petit-Aubert, B Pichot-Duclos, L Pivois, M Popelier, G Poulingue, M Priner, V Quipourt, M Rasamisoa, J-L Richard, V Rigalleau, N Roudat, C Sanz, J-M Serot, D Sifi, S Sirvain, A Slimani, E Sonnet, C Sosset, A Soualah, A Stroea, I Tauveron, J Timsit, M Tschudnowsky, A Vambergue, O Verier-Mine, M Virally
Publikováno v:
Diabetes & Metabolism. 41:301-303
The burden of hypoglycaemia is important, particularly in elderly type 2 diabetes (T2D) patients. Unfortunately, however, few studies are available concerning this population. GERODIAB is a prospective, multicentre, observational study that aims to d
Autor:
O. Verier-Mine
Publikováno v:
Diabetes & Metabolism. 36:595-616
Women with a history of gestational diabetes mellitus (GDM) are characterized by a high risk of type 2 diabetes mellitus (T2DM) (x 7), metabolic syndrome (x 2 to 5) and cardiovascular diseases (x 1,7). Women with lesser degrees of glucose intolerance
Autor:
Anne Vambergu, J. Lepercq, C. Vayssiere, P. Boulot, I. Burdet, G. Criballet, C. Fau, H. Grandjean, U. Simeoni, A. Vambergue, G. Beucher, A. Burguet, E. Cosson, P. Deruelle, F. Galtier, A.-M. Guedj, B. Guyard-Boileau, S. Hieronimus, S. Jacqueminet, M.-F. Jannot-Lamotte, V. Kerlan, M. Laloi-Michelin, J.-P. Le meaux, D. Mitanchez, O. Thiebaugeorges, O. Verier-Mine, M. Virally
Publikováno v:
Médecine des Maladies Métaboliques. 4:713-717
Autor:
J F, Gautier, P, Monguillon, O, Verier-Mine, P, Valensi, B, Fiquet, S, Dejager, B, Charbonnel
Publikováno v:
Diabetes research and clinical practice. 116
We conducted a pilot study to evaluate two therapeutic strategies at the time of insulin initiation in type 2 diabetic patients insufficiently controlled with metformin+insulin-secretagogues (IS, sulfonylureas or glinides). Patients were randomized t
Autor:
Catherine Cardot-Bauters, Rachel Desailloud, Marie-Françoise Odou, Marie-Christine Vantyghem, Bruno Carnaille, O. Verier-Mine, Emmanuelle Leteurtre, Nicole Porchet, Pascal Pigny
Publikováno v:
Europe PubMed Central
Multiple Endocrine Neoplasia type 1 (MEN1) is an autosomal dominant hereditary syndrome (OMIM 131100) due to MEN1 gene mutations, predisposing to the development of hyperplasic and tumoral lesions of neuroendocrine tissues. Since the identification o